Exacerbations

BROVANA: Fewer COPD patients reported exacerbations vs placebo1

Data from 2 identical 12-week, double-blind, placebo-controlled, randomized, multicenter trials (trials A & B) assessing the efficacy and tolerability of nebulized BROVANA 15 mcg twice daily (n=288) vs placebo (n=293) in patients with COPD. Exacerbation = an increase in symptoms leading to any change in baseline medication or additional medical attention (hospitalization, emergency room visit).

  • All patients (including those in placebo group) received rescue albuterol and supplemental ipratropium for use as needed throughout trial, except within 6 hours of PFT visit

BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.

References:

1. Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008;5(1):25-34.